Teva launches generic contraceptive pill

Teva

Ortho Tri-Cyclen tablets, marketed by Janssen Pharmaceuticals Inc., had annual sales of $488 million in the US.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced the launch of a generic equivalent of Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the US. Teva’s Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets, USP) is an oral contraceptive, available in a 28-day blister pack dispenser, used by women to prevent pregnancy.

Ortho Tri-Cyclen tablets, marketed by Janssen Pharmaceuticals Inc., had annual sales of $488 million in the US, according to IMS data as of October 2015.

Published by Globes [online], Israel business news - www.globes-online.com - on January 5, 2016

© Copyright of Globes Publisher Itonut (1983) Ltd. 2016

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2016